A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis

BACKGROUND Neuromyelitis optica is an inflammatory demyelinating disease with generally poor prognosis that selectively targets optic nerves and spinal cord. It is commonly misdiagnosed as multiple sclerosis. Neither disease has a distinguishing biomarker, but optimum treatments differ. The relation of neuromyelitis optica to optic-spinal multiple sclerosis in Asia is uncertain. We assessed the capacity of a putative marker for neuromyelitis optica (NMO-IgG) to distinguish neuromyelitis optica and related disorders from multiple sclerosis. METHODS Indirect immunofluorescence with a composite substrate of mouse tissues identified a distinctive NMO-IgG staining pattern, which we characterised further by dual immunostaining. We tested masked serum samples from 102 North American patients with neuromyelitis optica or with syndromes that suggest high risk of the disorder, and 12 Japanese patients with optic-spinal multiple sclerosis. Control patients had multiple sclerosis, other myelopathies, optic neuropathies, and miscellaneous disorders. We also established clinical diagnoses for 14 patients incidentally shown to have NMO-IgG among 85000 tested for suspected paraneoplastic autoimmunity. FINDINGS NMO-IgG outlines CNS microvessels, pia, subpia, and Virchow-Robin space. It partly colocalises with laminin. Sensitivity and specificity were 73% (95% CI 60-86) and 91% (79-100) for neuromyelitis optica and 58% (30-86) and 100% (66-100) for optic-spinal multiple sclerosis. NMO-IgG was detected in half of patients with high-risk syndromes. Of 14 seropositive cases identified incidentally, 12 had neuromyelitis optica or a high-risk syndrome for the disease. INTERPRETATION NMO-IgG is a specific marker autoantibody of neuromyelitis optica and binds at or near the blood-brain barrier. It distinguishes neuromyelitis optica from multiple sclerosis. Asian optic-spinal multiple sclerosis seems to be the same as neuromyelitis optica.

[1]  R. Mandler,et al.  Devic's neuromyelitis optica: A prospective study of seven patients treated with prednisone and azathioprine , 1998, Neurology.

[2]  Hans Lassmann,et al.  A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. , 2002, Brain : a journal of neurology.

[3]  J. Szurszewski,et al.  Immunization with neuronal nicotinic acetylcholine receptor induces neurological autoimmune disease. , 2003, The Journal of clinical investigation.

[4]  Y. Itoyama,et al.  Pure optic-spinal form of multiple sclerosis in Japan. , 2002, Brain : a journal of neurology.

[5]  D. Silberberg,et al.  New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.

[6]  K. Campbell,et al.  Deletion of brain dystroglycan recapitulates aspects of congenital muscular dystrophy , 2002, Nature.

[7]  E. Benarroch,et al.  CRMP‐5 neuronal autoantibody: Marker of lung cancer and thymoma‐related autoimmunity , 2001, Annals of neurology.

[8]  P. Vermersch,et al.  Is Devic's neuromyelitis optica a separate disease? A comparative study with multiple sclerosis , 2003, Multiple sclerosis.

[9]  R S Howard,et al.  Clinical, CSF, and MRI findings in Devic's neuromyelitis optica. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[10]  A. Vincent,et al.  Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies , 2001, Nature Medicine.

[11]  B. Weinshenker,et al.  Neuromyelitis optica: what it is and what it might be , 2003, The Lancet.

[12]  B. Weinshenker,et al.  Plasma exchange for severe attacks of CNS demyelination: Predictors of response , 2002, Neurology.

[13]  P C O'Brien,et al.  The clinical course of neuromyelitis optica (Devic’s syndrome) , 1999, Neurology.

[14]  J. Kira Multiple sclerosis in the Japanese population , 2003, The Lancet Neurology.

[15]  R. Mandler,et al.  Devic's neuromyelitis optica: A clinicopathological study of 8 patients , 1993, Annals of neurology.

[16]  D S Goodin,et al.  Disease modifying therapies in multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines , 2002, Neurology.

[17]  D. Li,et al.  Magnetic resonance imaging of the head in the diagnosis of multiple sclerosis: A prospective 2‐year follow‐up with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT , 1991, Neurology.